Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.

被引：7

作者：

O'Malley, David M.

Moore, Kathleen N.

Vergote, Ignace

Martin, Lainie P.

Gilbert, Lucy

Martin, Antonio Gonzalez

Nepert, Dale L.

Ruiz-Soto, Rodrigo

Birrer, Michael J.

Matulonis, Ursula A.

机构：

[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[3] Univ Leuven, Leuven Canc Inst, Leuven, Belgium

[4] BGOG, Leuven, Belgium

[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[6] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[7] Grupo Espanol Invest Canc Ovario GEICO, Madrid, Spain

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] ImmunoGen Inc, Waltham, MA USA

[10] Massachusetts Gen Hosp, Boston, MA 02114 USA

[11] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.5553

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5553

引用

页数：4

共 28 条

[1] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts).
Moore, Kathleen N.
Martin, Lainie P.
Matulonis, Ursula A.
Konner, Jason A.
Seward, Shelly Marie
Bauer, Todd Michael
O'Malley, David M.
Perez, Raymond P.
Jeong, Woondong
Zhou, Yinghui
Kirby, Maurice William
Mohanavelu, Satishkumar
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Richardson, Debra L.
Moore, Kathleen N.
Vergote, Ignace
Gilbert, Lucy
Martin, Lainie P.
Mantia-Smaldone, Gina M.
Castro, Cesar M.
Provencher, Diane
Matulonis, Ursula A.
Stec, James
Wang, Yuemei
Method, Michael
O'Malley, David M.
GYNECOLOGIC ONCOLOGY, 2024, 185 : 186 - 193
[4] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
O'Malley, David M.
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Vergote, Ignace
Martin, Lainie P.
Mantia-Smaldone, Gina
Gilbert, Lucy
Gonzalez-Martin, Antonio
Bratos, Raquel
Esteves, Brooke
Malek, Karim S.
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
O'Malley, David M.
Martin, Lainie P.
Gilbert, Lucy
Vergote, Ignace
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Malek, Karim S.
Gonzalez-Martin, Antonio
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Moore, Kathleen N.
O'Malley, David M.
Vergote, Ignace
Martin, Lainie P.
Gonzalez-Martin, Antonio
Malek, Karim
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 46 - 52
[7] Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
O'Malley, D.
Richardson, D.
Vergote, I. B.
Gilbert, L.
Martin, L. P.
Mantia-Smaldone, G. M.
Castro, C.
Provencher, D.
Matulonis, U. A.
Malek, K.
Moore, K. N.
ANNALS OF ONCOLOGY, 2019, 30
[8] Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina M.
Lim, Peter C.
Castro, Cesar M.
Provencher, Diane
Memarzadeh, Sanaz
Method, Michael
Wang, Jiuzhou
Moore, Kathleen N.
O'Malley, David M.
GYNECOLOGIC ONCOLOGY, 2023, 170 : 241 - 247
[9] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
Moore, Kathleen N.
Borghaei, Hossein
O'Malley, David M.
Jeong, Woondong
Seward, Shelly M.
Bauer, Todd M.
Perez, Raymond P.
Matulonis, Ursula A.
Running, Kelli L.
Zhang, Xiaoyan
Ponte, Jose F.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
CANCER, 2017, 123 (16) : 3080 - 3087
[10] FORWARD II: A phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FRα)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer.
O'Malley, David M.
Martin, Lainie P.
Moore, Kathleen N.
Nepert, Dale L.
Ruiz-Soto, Rodrigo
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 →